Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC5733 | FR 139317 |
| A highly potent and selective ETA endothelin receptor antagonist (Ki values are 1 nM and 7.3 μM at ETA and ETB subtypes respectively). Active in vivo. | |
| BCC5735 | DL-TBOA |
| A competitive, non-transportable blocker of excitatory amino acid transporters (IC50 values are 70, 6, and 6 μM for EAAT1, EAAT2 and EAAT3 respectively). Also inhibits EAAT4 and EAAT5 (Ki values are 4.4 and 3.2 μM respectively). Displays high selectivity for EAATs over ionotropic and metabotropic glutamate receptors. Also available as part of the Excitatory Amino Acid Transporter Inhibitor. | |
| BCC5741 | RS 100329 hydrochloride |
| Subtype-selective α1A-adrenoceptor antagonist (pKi = 9.6 for human cloned α1A receptors). Displays 126- and 50-fold selectivity over human α1B and α1D receptors respectively. Active in vivo. | |
| BCC5743 | α-Conotoxin MII |
| Highly potent and selective competitive antagonist for α3β2 subunit-containing nicotinic receptors (IC50 = 0.5 - 3.5 nM at α3β2 expressed in Xenopus oocytes). Also potently blocks β3-containing neuronal nicotinic receptors. Displays > 200-fold selectivity for α3β2 over α2β2, α4β2 and α3β4. | |
| BCC5746 | UB 165 fumarate |
| Subtype-selective nicotinic agonist. Full agonist at α3β2- and very weak partial agonist at α4β2- containing nAChRs. Ki values are 0.27, 20 (IC50), 2790 and 990 nM for α4β2, α3, α7 and α1β1δε respectively. | |
| BCC5753 | MRS 1334 |
| Potent and highly selective antagonist for the human adenosine A3 receptor. Ki values are 2.69 nM at hA3, and > 100 μM at rat A1 and rat A2A receptors. | |
| BCC5755 | Ac-RYYRWK-NH2 |
| Potent, selective partial agonist peptide for the NOP receptor (Ki = 0.71 nM). Selective over μ, δ and κ opioid receptors (IC50 > 4000 nM). Increases food intake in vivo. | |
| BCC5757 | Naloxone benzoylhydrazone |
| Mixed opioid receptor agonist/antagonist. Acts as a potent and full agonist at κ, a partial agonist at μ and δ opioid receptors (pEC50 values are 9.45, 8.74 and 8.61 in a cAMP assay, 9.70, 8.59 and 8.49 in a [35S]GTPγS binding assay respectively). Fails to exert agonist effects at NOP receptors and antagonizes agonist-induced NOP activation. Stimulates κ-, μ- and δ-mediated analgesia and blocks NOP-induced supraspinal nociception. | |
